Please assess the completion status of the following clinical trial:

Trial Title: Fludarabine With or Without Cyclophosphamide in Treating Patients With Advanced Chronic Lymphocytic Leukemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Confirmed diagnosis of previously untreated chronic lymphocytic leukemia (CLL)~  * Binet stage C and stage B are acceptable if there is rapid disease progression, symptoms of enlarged lymph nodes and organs, or severe B-symptoms~ * Binet stage A is acceptable, if there are B-symptoms~PATIENT CHARACTERISTICS:~* ECOG performance status 0-2~* Life expectancy \> 6 months~* No severe organ dysfunction~* No other previous or concurrent neoplasms, autoimmune hemolytic anemia, or thrombocytopenia~PRIOR CONCURRENT THERAPY:~* No prior or concurrent chemotherapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Fludarabine plus Cyclophosphamide (Type: ACTIVE_COMPARATOR): None
- Fludarabine (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).